(Circulation. 2000;102:104.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Contrasting Efficacy of Dofetilide in Differing Experimental Models of Atrial Fibrillation
From the Research Center and Department of Medicine, Montreal Heart Institute (D.L., A.B., S.N.); the Department of Medicine, University of Montreal (S.N.); and the Department of Pharmacology, McGill University (S.N.), Montreal, Quebec, Canada.
Correspondence to Stanley Nattel, Montreal Heart Institute, 5000 Belanger St E, Montreal, Quebec, Canada H1T 1C8. E-mail nattel{at}icm.umontreal.ca
Background—Rapid atrial pacing (RAP) and congestive heart failure (CHF) produce different experimental substrates for atrial fibrillation (AF). We tested the hypothesis that AF maintained by different substrates responds differently to antiarrhythmic-drug therapy.
Methods and Results—The class III antiarrhythmic agent dofetilide was given intravenously at doses of 10 (D10) and 80 (D80) µg/kg to dogs with AF induced either (1) after 7 days of RAP at 400 bpm or (2) in the presence of CHF induced by rapid ventricular pacing. Dofetilide terminated AF in all CHF dogs, but D10 failed to terminate AF in any RAP dog, and D80 terminated AF in only 1 of 5 RAP dogs (20%) (P<0.01 for efficacy in CHF versus RAP dogs). Dofetilide was highly effective in preventing AF induction by atrial burst pacing in dogs with CHF but was totally ineffective in dogs with RAP. Dofetilide increased atrial effective refractory period and AF cycle length to a greater extent in CHF dogs. Epicardial mapping with 248 bipolar electrodes showed that CHF-related AF was often due to macroreentry, with dofetilide terminating AF by causing block in reentry circuits. RAP-related AF was due to multiple–wave front reentry, with dofetilide slowing reentry and decreasing the number of simultaneous waves, but not sufficiently to stop AF.
Conclusions—The mechanism underlying AF importantly influences dofetilide efficacy. The dependence of drug efficacy in AF on the underlying mechanism has potentially significant implications for antiarrhythmic drug use and development and may explain the well-known therapeutic resistance of longer-duration AF.
Key Words: arrhythmia • dofetilide • ventricles • remodeling
This article has been cited by other articles:
 |
|
 |
|
  P. Comtois, M. Sakabe, E. J. Vigmond, M. Munoz, A. Texier, A. Shiroshita-Takeshita, and S. Nattel Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1489 - H1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Regan, L. Kiss, G. L. Stump, C. J. McIntyre, D. C. Beshore, N. J. Liverton, C. J. Dinsmore, and J. J. Lynch Jr. Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 322 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy Cardiovasc Res, April 1, 2007; 74(1): 104 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mykytsey, J. L. Bauman, M. Razminia, T. Zheutlin, T. Wang, M. Saleem, S. Leal, and R. F. Kehoe Observations on the Safety and Effectiveness of Dofetilide in Patients With Paroxysmal Atrial Fibrillation and Normal Left Ventricular Function Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 36 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Bollmann First comes diagnosis then comes treatment: an underappreciated paradigm in atrial fibrillation management Eur. Heart J., December 1, 2005; 26(23): 2487 - 2489. [Full Text] [PDF]
|
|
|
|
|
|
M. Duytschaever, Y. Blaauw, and M. Allessie Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs Cardiovasc Res, July 1, 2005; 67(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hayashi, C. Omichi, Y. Miyauchi, W. J. Mandel, S.-F. Lin, P.-S. Chen, and H. S. Karagueuzian Age-related sensitivity to nicotine for inducible atrial tachycardia and atrial fibrillation Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2091 - H2098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-F. Tse and C.-P. Lau Electrophysiologic actions of dl-sotalolin patients with persistent atrial fibrillation J. Am. Coll. Cardiol., December 18, 2002; 40(12): 2150 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kneller, R. Zou, E. J. Vigmond, Z. Wang, L. J. Leon, and S. Nattel Cholinergic Atrial Fibrillation in a Computer Model of a Two-Dimensional Sheet of Canine Atrial Cells With Realistic Ionic Properties Circ. Res., May 17, 2002; 90 (9): e73 - e87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jalife, O. Berenfeld, and M. Mansour Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 204 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F Bosch and S. Nattel Cellular electrophysiology of atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 259 - 269. [Full Text] [PDF]
|
|
|
|
|
|
A. Shimizu and O. A. Centurion Electrophysiological properties of the human atrium in atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 302 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shinagawa, D. Li, T. K. Leung, and S. Nattel Consequences of Atrial Tachycardia-Induced Remodeling Depend on the Preexisting Atrial Substrate Circulation, January 15, 2002; 105(2): 251 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shi, A. Ducharme, D. Li, R. Gaspo, S. Nattel, and J.-C. Tardif Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation Cardiovasc Res, November 1, 2001; 52(2): 217 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Polontchouk, J.-A. Haefliger, B. Ebelt, T. Schaefer, D. Stuhlmann, U. Mehlhorn, F. Kuhn-Regnier, E. R. De Vivie, and S. Dhein Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria J. Am. Coll. Cardiol., September 1, 2001; 38(3): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Derakhchan, C. Villemaire, M. Talajic, and S. Nattel The class III antiarrhythmic drugs dofetilide and sotalol prevent AF induction by atrial premature complexes at doses that fail to terminate AF Cardiovasc Res, April 1, 2001; 50(1): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel and D. Li Ionic Remodeling in the Heart : Pathophysiological Significance and New Therapeutic Opportunities for Atrial Fibrillation Circ. Res., September 15, 2000; 87(6): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Doshi and B. N. Singh Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 237 - 247. [PDF]
|
|
|
|
|
|
D. Li, L. Zhang, J. Kneller, and S. Nattel Potential Ionic Mechanism for Repolarization Differences Between Canine Right and Left Atrium Circ. Res., June 8, 2001; 88(11): 1168 - 1175. [Abstract] [Full Text] [PDF]
|
|